Clinical trials: Hepatitis; Epidemic
Hepatitis C, Chronic
Rate and Predictors of Relapse in the Treatment of Hepatitis C (Study P05181)
This is an observational, multicenter, nationwide study where information will be collected on the follow-up of participants with chronic hepatitis C virus (HCV) who have a viral response at the end of treatment with pegylated…
- Trial name
- FAST-4 (NCT00723645)
- Volunteers
- 279 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C
Use-Results Surveillance Study of Harvoni® in Japanese Patients With Chronic Genotype 1 Hepatitis C Virus Infection
This study will evaluate the safety and efficacy of Harvoni® (ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC)) treatment under real world use in Japan.
- Trial name
- NCT02591277
- Testing
- Harvoni
- Where
- 125 sites in Japan
- Volunteers
- 3,294 people
- Sponsor
- Gilead Sciences
Chronic Hepatitis B
Study to Compare the Safety and Pharmacokinetics of CKD-390 Tablet With Viread® Tablet
The purpose of this study is to compare the safety and pharmacokinetics of CKD-390(Tenofovir Disoproxil Aspartate) and Viread® tablet(Tenofovir Disoproxil Fumarate) in healthy male volunteers.
- Trial name
- NCT02589457
- Testing
- CKD-390, Viread® tablet
- Where
- South Korea
- Volunteers
- 40 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Hepatitis B
Hepatitis B Vaccination Through Syringe Exchange Programs: A Randomized, Controlled Trial of Vaccination Schedules
The investigators seek to provide immunization for individuals who are at high risk of contracting hepatitis B virus (HBV) infection because of their illicit drug use.
- Trial name
- HVS (NCT01259453)
- Testing
- Vaccination to prevent hepatitis B virus infection
- Where
- 3 sites in United States
- Volunteers
- 595 people, healthy volunteers welcome
- Sponsor
- Yale University
Hepatitis C
Study of Maternal Hepatitis C Infection and Influenza Vaccination in Pregnancy
The purpose of this study is to determine if hepatitis C virus and influenza virus vaccine components can cross the placenta and stimulate an immune response in the fetus.
- Trial name
- NCT00810875
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of California, San Francisco
Hepatitis C, HIV Infections
Immune Response to Hepatitis C Virus
The purpose of the study is to investigate the immune response to hepatitis C virus to determine why some people clear the virus and others develop chronic infection.
- Trial name
- NCT00165919
- Testing
- None. Not a clinical trial. Specimens taken for basic research in laboratory.
- Volunteers
- healthy volunteers welcome
- Sponsor
- Emory University
Chronic Hepatitis C
The Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, ± Dasabuvir, ± Ribavirin in France
This study seeks to determine the effectiveness of the interferon-free ABBVIE REGIMEN ± ribavirin (RBV) in participants with chronic hepatitis C (CHC) virus in clinical practices across France.
- Trial name
- OPALE (NCT02618928)
- Where
- 70 sites in France
- Volunteers
- 735 people
- Sponsor
- AbbVie
Hepatitis C
ETHOS ENGAGE: Enhancing Treatment of Hepatitis C in Opioid Substitution Settings
The overall goals of the ETHOS II Project are to enhance hepatitis C virus (HCV) care in drug treatment clinics and needle and syringe programs (NSPs) in New South Wales and Australia, and to develop a translational framework for…
- Trial name
- ETHOS II (NCT03685045)
- Testing
- Campaign days
- Where
- 32 sites in Australia
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- Kirby Institute
Human Immunodeficiency Virus, Hepatitis B
Notification of Donors With Positive Microbiology Markers
Each year around 200 blood donors in the UK are found to be infected with blood-borne diseases (HIV, hepatitis B, hepatitis C, and HTLV), while several others have been identified as having an increased risk of variant…
- Conditions
- Human Immunodeficiency Virus, Hepatitis B, Hepatitis C, Human T-lymphotropic Virus I & II
- Trial name
- NCT01050881
- Where
- United Kingdom
- Volunteers
- 217 people
- Sponsor
- NHS Blood and Transplant
Hepatitis C
Can Vitamin D Supplementation Improve Hepatitis C Cure Rates
Evidence suggests that vitamin D may be directly or indirectly a co-factor for the efficacy of Hepatitis C virus, (HCV), antiviral therapies.
- Trial name
- ViaDUCT (NCT02053519)
- Testing
- Active Comparator: Vigantol Oil (Vitamin D3), Mygliol Oil
- Where
- 8 sites in United Kingdom
- Volunteers
- 72 people
- Sponsor
- University of Dundee
Genotype 4 Chronic Hepatitis C Infection
Boceprevir With Peginterferon Alfa-2b and Ribavirin in the Treatment-naive Patients Infected With Genotype 4 Chronic Hepatitis C Infection
Hypothesis Combination of Boceprevir with Ribavirin in treatment-naïve patients with genotype 4 chronic hepatitis C infection will increase the proportion of patients achieving sustained viral response compared to standard…
- Trial name
- NCT01653236
- Testing
- Boceprevir, Peginterferon alfa-2b, ribavirin
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Theodor Bilharz Research Institute
Hepatitis C
Telaprevir in Genotype 3 HCV
Patients with genotype 3 hepatitis C who have advanced liver disease (cirrhosis) have a very high chance of developing fatal complications of their disease unless they receive effective treatment.
- Trial name
- TIG3 (NCT02087111)
- Testing
- Telaprevir, 40 Kd Pegylated interferon alfa 2a, Ribavirin
- Where
- 4 sites in United Kingdom
- Volunteers
- 14 people
- Sponsor
- Queen Mary University of London
HIV Infections
Study of Tenofovir Disoproxil Fumarate (TDF) for Prevention of HIV
This Phase 2 study involving tenofovir disoproxil fumarate (TDF) will assess the extended safety of TDF 300 mg per day among young women who are not HIV-infected.
- Trial name
- NCT00122486
- Testing
- Tenofovir Disoproxil Fumarate
- Where
- 3 sites in Cameroon, Ghana and 1 more
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- FHI 360
Hepatitis C, Chronic
Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir/Pibrentasvir in Chronic Hepatitis C Patients
The aim of this study is to determine if treatment monitoring schedule for chronic HCV patients treated with glecaprevir (300mg)/pibrentasvir (120mg) can be simplified.
- Trial name
- SMART-C (NCT03117569)
- Testing
- glecaprevir (300mg)/pibrentasvir (120mg)
- Where
- 33 sites in United States, Australia and 6 more
- Volunteers
- 380 people
- Sponsor
- Kirby Institute
Chronic Hepatitis C, Atherosclerosis
Hepatitis C Treatment and Atherosclerosis
This study will examine the effects of treatment for hepatitis C on atherosclerosis, or hardening of the arteries. Hepatitis C is a disease of the liver caused by a virus that can cause permanent damage to that organ.
- Trial name
- NCT00659256
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Chronic Hepatitis B
Telbivudine Versus Adefovir Dipivoxil in Adults With HBegAg-Positive, Compensated Chronic Hepatitis B
This research study is being conducted to compare the safety and effectiveness of the investigational medication, LdT (telbivudine) versus adefovir dipivoxil, a drug approved by the Food and Drug Administration (FDA) for the…
- Trial name
- NCT00115245
- Testing
- Telbivudine (LdT), Adefovir Dipivoxil
- Where
- 15 sites in United States, Australia and 7 more
- Sponsor
- Novartis
Chronic Hepatitis C
Phase 2 Study of VX-950, Pegasys® With and Without Copegus® in Hepatitis C
Compare the effectiveness of telaprevir (VX-950) in combination with Pegylated Interferon Alfa 2a (Peg-IFN-alfa-2a) with and without Ribavirin (RBV) in reducing plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels
- Trial name
- NCT00372385
- Testing
- Ribavirin, Pegylated Interferon Alfa 2a, Telaprevir
- Where
- 4 sites in Austria, France and 2 more
- Volunteers
- 334 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Chronic Hepatitis B
Pegasys Plus Entecavir Versus Entecavir Versus Pegasys for Hepatitis B e Antigen-Negative Chronic Hepatitis B
Currently, there are several antiviral treatments effective for suppression of viral replication but still failed to cure HBV infection in patients with chronic hepatitis B (CHB).
- Trial name
- NCT01925820
- Testing
- Pegasys&Entecavir
- Where
- Taiwan
- Volunteers
- 540 people
- Sponsor
- National Taiwan University Hospital
Hepatitis B, Hepatitis B Infection
Diagnostic Sensitivity and Specificity of iStatis HBsAg Test at the Point-Of-Care Site Settings
A prospective cross-sectional study in which surgically non-invasive sample-taking is done only for the purpose of testing the samples on iStatis HBsAg Test at the point of care.
- Trial name
- NCT06368479
- Testing
- iStatis HBsAg Test
- Where
- South Africa
- Volunteers
- 1,400 people
- Sponsor
- bioLytical Laboratories
Hepatitis C
An Efficacy, Safety and Tolerability Study of TMC435 in Genotype 1 Hepatitis C-infected Patients Who Relapsed After Previous Therapy
The purpose of this study is to investigate the effectiveness and safety of TMC435 compared with placebo in patients who are infected with genotype 1 hepatitis C virus who relapsed after previous interferon-based therapy.
- Trial name
- PROMISE (NCT01281839)
- Testing
- TMC435, Peginterferon alpha-2a (PegIFN alpha-2a), Ribavirin (RBV)
- Where
- 68 sites in United States, Australia and 11 more
- Volunteers
- 394 people
- Sponsor
- Janssen R&D Ireland
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.